Alliancebernstein L.P. Sells 8,564 Shares of Haemonetics Co. (NYSE:HAE)

Alliancebernstein L.P. reduced its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 7.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,781 shares of the medical instruments supplier's stock after selling 8,564 shares during the period. Alliancebernstein L.P. owned about 0.20% of Haemonetics worth $7,791,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Whittier Trust Co. bought a new position in shares of Haemonetics during the fourth quarter valued at approximately $62,000. Parkside Financial Bank & Trust lifted its position in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 240 shares during the period. AlphaQuest LLC grew its holdings in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after acquiring an additional 1,826 shares during the period. KBC Group NV lifted its holdings in Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after acquiring an additional 712 shares during the last quarter. Finally, HighTower Advisors LLC boosted its position in shares of Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after purchasing an additional 244 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Barrington Research dropped their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price objective for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. JMP Securities decreased their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a report on Friday, February 7th. Finally, Needham & Company LLC reduced their price objective on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Stock Performance

Shares of HAE stock traded up $0.39 during trading on Thursday, reaching $57.28. The company had a trading volume of 82,067 shares, compared to its average volume of 688,116. The firm's 50 day simple moving average is $63.22 and its two-hundred day simple moving average is $73.07. Haemonetics Co. has a one year low of $55.30 and a one year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market capitalization of $2.88 billion, a PE ratio of 22.56, a PEG ratio of 1.11 and a beta of 0.41.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.